Cue Biopharma, Inc. Common Stock (CUE) Stock
Key stats
- Market cap
- $135.55M
- Price / Earnings ratio
- -0.8x
- EPS (TTM)
- -$26.42
- Volume
- Loading
- 52-week high
- $45.50
- 52-week low
- $0.17
Source: third-party data provider, as of November 13, 2026
Compare with CUE
Recent news
Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response
CUE
Nasdaq, S&P 500 Futures Take A Breather Near Highs: Why AAPL, META, RDDT, RBLX, CUE Are Keeping Traders Engaged Today
Nasdaq, S&P 500 Futures Take A Breather Near Highs: Why AAPL, META, RDDT, RBLX, CUE Are Keeping Traders Engaged Today
CUE
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally?
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally?
CUECUE Stock On Track For Best Day In History — Why Is Retail Optimistic?
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?
CUENews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.41
- MACD 12/26/9
- -1.25
- EMA 9 of MACD
- -1.52
- MACD histogram
- 0.27
- SMA 50
- $24.36
- Price below SMA 50
- EMA 50
- $22.72
- Price below EMA 50
- SMA 200
- $21.51
- Price below SMA 200
- EMA 200
- $20.69
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response
CUENasdaq, S&P 500 Futures Take A Breather Near Highs: Why AAPL, META, RDDT, RBLX, CUE Are Keeping Traders Engaged Today
Nasdaq, S&P 500 Futures Take A Breather Near Highs: Why AAPL, META, RDDT, RBLX, CUE Are Keeping Traders Engaged Today
CUECUE Stock Jumps Over 100% After Hours — What’s Driving The Rally?
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally?
CUECUE Stock On Track For Best Day In History — Why Is Retail Optimistic?
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?
CUECUE Stock Slips As CEO Leaves After Just Six Months In Role
CUE Stock Slips As CEO Leaves After Just Six Months In Role
CUE
3 Biotech Stocks Sitting on Huge-Upside Catalysts
3 Biotech Stocks Sitting on Huge-Upside Catalysts
CUE
7 Hot Growth Stocks Poised to Triple in 2023
7 Hot Growth Stocks Poised to Triple in 2023
CUENews tone: automated (AI) classification of the article's content, not a price prediction.
About Cue Biopharma, Inc. Common Stock
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Shao-Lee Lin M.D., Ph.D. | President, CEO & Director | 1967 |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific & Clinical Advisory Board | 1961 |
| Mr. James M. Ahlers | Chief Financial Officer | 1964 |
| Ms. Lucinda Warren | Principal Accounting Officer & Chief Business Officer | 1969 |
| Mr. Colin G. Sandercock J.D., MSE | Senior Vice President of Intellectual Property | 1957 |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder | 1976 |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder | 1973 |
| Ms. Agnes Lee | Chief Officer of Public & Investor Relations | — |
| Ms. Sumita Ray J.D. | Chief Legal & Compliance Officer and Corporate Secretary | 1974 |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer | 1950 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 43.41
- MACD 12/26/9
- -1.25
- EMA 9 of MACD
- -1.52
- MACD histogram
- 0.27
- SMA 50
- $24.36
- Price below SMA 50
- EMA 50
- $22.72
- Price below EMA 50
- SMA 200
- $21.51
- Price below SMA 200
- EMA 200
- $20.69
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $83.00
- Average
- $83.00
- High
- $83.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | -28.0 | +31.1 | -5.3 | -5.0 | -9.0 | -17.3 | -3.9 |
Corporate actions
Upcoming
No upcoming corporate actions for CUE
